Glecaprevir–pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies—a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2)

Open Label ◽

Phase 3 ◽

Double Blind ◽

Multicentre Phase ◽

Glecaprevir/Pibrentasvir to Treat Chronic Hepatitis C Virus Infection in Asia: Two Multicentre, Phase 3 Studies – A Randomised, Double-Blind Study (VOYAGE-1) and an Open-Label, Single-Arm Study (VOYAGE-2)

SSRN Electronic Journal ◽

10.2139/ssrn.3514708 ◽

2020 ◽

Author(s):

Lai Wei ◽

Guiqiang Wang ◽

Negar N. Alami ◽

Wen Xie ◽

Jeong Heo ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Double Blind Study ◽

Open Label ◽

Phase 3 ◽

Double Blind ◽

Multicentre Phase ◽

Seraprevir and sofosbuvir for treatment of chronic hepatitis C virus infection: A single‐arm, open‐label, phase 3 trial

Journal of Gastroenterology and Hepatology ◽

10.1111/jgh.15412 ◽

2021 ◽

Author(s):

Fei Kong ◽

Xiaoyu Wen ◽

Xiaofeng Wen ◽

Xiaozhong Wang ◽

Guicheng Wu ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Virus Infection ◽

Chronic Hepatitis C ◽

Open Label ◽

Phase 3 ◽

Open Label Phase

Safety and efficacy of an all-oral interferon-free regimen of seraprevir, an NS3/4A protease inhibitor and sofosbuvir in patients with chronic hepatitis C virus (HCV) genotype 1: an open-label, multicentre, phase 3 trial

Journal of Hepatology ◽

10.1016/s0168-8278(20)31163-6 ◽

2020 ◽

Vol 73 ◽

pp. S330

Author(s):

Xiaoyu Wen ◽

Fei Kong ◽

Xiaofeng Wen ◽

Xiaozhong Wang ◽

Shide Lin ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Genotype 1 ◽

Open Label ◽

Phase 3 ◽

Safety And Efficacy ◽

Multicentre Phase ◽

Hcv Genotype 1

Sofosbuvir–velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial

The Lancet Gastroenterology & Hepatology ◽

10.1016/s2468-1253(18)30343-1 ◽

2019 ◽

Vol 4 (2) ◽

pp. 127-134 ◽

Cited By ~ 32

Author(s):

Lai Wei ◽

Seng Gee Lim ◽

Qing Xie ◽

Kính Nguyen Văn ◽

Teerha Piratvisuth ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Virus Infection ◽

Chronic Hepatitis C ◽

Open Label ◽

Phase 3 ◽

Open Label Phase

Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial

The Lancet Infectious Diseases ◽

10.1016/s1473-3099(17)30496-6 ◽

2017 ◽

Vol 17 (10) ◽

pp. 1062-1068 ◽

Cited By ~ 178

Author(s):

Xavier Forns ◽

Samuel S Lee ◽

Joaquin Valdes ◽

Sabela Lens ◽

Reem Ghalib ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Genotype 1 ◽

Virus Genotype ◽

Open Label ◽

Phase 3 ◽

Multicentre Phase ◽

Compensated Cirrhosis ◽

Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: A single‐arm, open‐label, phase 3 trial

Liver International ◽

10.1111/liv.14633 ◽

2020 ◽

Vol 40 (11) ◽

pp. 2685-2693

Author(s):

Yanhang Gao ◽

Fei Kong ◽

Guangming Li ◽

Cheng Li ◽

Sujun Zheng ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Virus Infection ◽

Chronic Hepatitis C ◽

Open Label ◽

Phase 3 ◽

Open Label Phase

Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis

Gastroenterology ◽

10.1053/j.gastro.2015.07.001 ◽

2015 ◽

Vol 149 (4) ◽

pp. 971-980.e1 ◽

Cited By ~ 59

Author(s):

Eric Lawitz ◽

Mihály Makara ◽

Ulus Salih Akarca ◽

Paul J. Thuluvath ◽

Liliana Lucia Preotescu ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Virus Infection ◽

Efficacy And Safety ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial

The Lancet ◽

10.1016/s0140-6736(15)60159-3 ◽

2015 ◽

Vol 385 (9986) ◽

pp. 2502-2509 ◽

Cited By ~ 187

Author(s):

Christophe Hézode ◽

Tarik Asselah ◽

K Rajender Reddy ◽

Tarek Hassanein ◽

Marina Berenguer ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Virus Infection ◽

Open Label ◽

Genotype 4 ◽

Treatment Naïve ◽

Open Label Trial

Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study

Journal of Hepatology ◽

10.1016/j.jhep.2004.11.025 ◽

2005 ◽

Vol 42 (3) ◽

pp. 315-322 ◽

Cited By ~ 171

Author(s):

Nizar N. Zein ◽

for the Etanercept Study Group

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Controlled Study ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Treatment Naïve

Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial

The Lancet Gastroenterology & Hepatology ◽

10.1016/s2468-1253(18)30341-8 ◽

2019 ◽

Vol 4 (1) ◽

pp. 45-51 ◽

Cited By ~ 27

Author(s):

Tarik Asselah ◽

Samuel S Lee ◽

Betty B Yao ◽

Tuan Nguyen ◽

Florence Wong ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Efficacy And Safety ◽

Virus Genotype ◽

Open Label ◽

Multicentre Phase ◽

Genotype 5